07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

AZD3965: Phase I started

Cancer Research U.K. began a 2-part, open-label, dose-escalation, U.K. Phase I trial to evaluate 5, 10, 20 and 30 mg oral AZD3965 given once or twice daily in 28-day cycles for up to 6 cycles...
07:00 , Aug 15, 2011 |  BioCentury  |  Product Development

Powering down cancer

The cancer metabolism field has been heating up over the last five years, and now is beginning to produce some of the first data for compounds aimed at stunting aerobic glycolysis, the energy-generating process that...